Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT

[1]  M. O’connell,et al.  Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience , 2018, American journal of hematology.

[2]  R. Hills,et al.  Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Ogawa,et al.  Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients , 2018, Leukemia & lymphoma.

[4]  G. Mufti,et al.  Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission , 2017, Oncotarget.

[5]  G. Mufti,et al.  Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  R. Stone.  Which new agents will be incorporated into frontline therapy in acute myeloid leukemia? , 2017, Best practice & research. Clinical haematology.

[7]  Dan Yang,et al.  The progress and current status of immunotherapy in acute myeloid leukemia , 2017, Annals of Hematology.

[8]  Yan-rong Liu,et al.  Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis , 2017, Journal of Hematology & Oncology.

[9]  B. Sandmaier,et al.  Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis , 2017, Cancer.

[10]  B. Sandmaier,et al.  Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission , 2017, Cancer.

[11]  J. Lancet,et al.  What are the most promising new agents in acute myeloid leukemia? , 2017, Current opinion in hematology.

[12]  E. Leifer,et al.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Ganser,et al.  Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[15]  M. Hallek,et al.  FLAMSA reduced‐intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission , 2016, European journal of haematology.

[16]  M. Labopin,et al.  Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission , 2016, Bone Marrow Transplantation.

[17]  E. Atenafu,et al.  Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study , 2016, Bone Marrow Transplantation.

[18]  Asim Khwaja,et al.  Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.

[19]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[20]  H. Kantarjian,et al.  New drugs in acute myeloid leukemia. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Labopin,et al.  Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects , 2015, Bone Marrow Transplantation.

[22]  M. Sorror,et al.  Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  J. Lipton,et al.  Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2 , 2015, Bone Marrow Transplantation.

[24]  E. Vellenga,et al.  Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years , 2014, Leukemia.

[25]  R. Gale,et al.  Should persons with acute myeloid leukemia have a transplant in first remission? , 2014, Leukemia.

[26]  M. Eapen.  Unrelated donor transplantation: peripheral blood or bone marrow--does it matter? , 2014, Best practice & research. Clinical haematology.

[27]  H. Dombret,et al.  Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. , 2014, Blood.

[28]  J. Lipton,et al.  Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  R. Gale,et al.  Correcting 2 more myths regarding transplants for AML in second remission. , 2014, Blood.

[30]  F. Appelbaum.  Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[31]  J. Lipton,et al.  Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR , 2013, Bone Marrow Transplantation.

[32]  R. Hills,et al.  Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Rowe,et al.  The myth of the second remission of acute leukemia in the adult. , 2013, Blood.

[34]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[35]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[37]  M. Shimoyama,et al.  Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse , 2010, Haematologica.

[38]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[39]  M. Maris,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[42]  Harriet Noreen,et al.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. , 2007, Blood.

[43]  Augustin Ferrant,et al.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.

[44]  J. Bourhis,et al.  Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Ce , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[46]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Tiercy,et al.  Selection of unrelated bone marrow donors by serology, molecular typing and cellular assays. , 2002, Transplant immunology.

[48]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[49]  J P Klein,et al.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.

[50]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[51]  P. Hougaard,et al.  Frailty models for survival data , 1995, Lifetime data analysis.

[52]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.